REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
04 October 2023
Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market
27 September 2023
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
End of Q4 update from REPROCELL (2022-23)
04 May 2023
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
03 May 2023
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
28 February 2023
End of Q3 update from REPROCELL (2022-23)
12 December 2022
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
23 November 2022
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
04 October 2022
End of Q2 update from REPROCELL (2022-23)
03 October 2022
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
Life science after lockdown: SPS returns for 2022
15 August 2022
REPROCELL is On the Road at ISSCR 2022
07 June 2022
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
REPROCELL signs agency agreement with Ajinomoto Group for the marketing and sales of StemFit Basic03 GMP
08 November 2021
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant
21 June 2021
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
24 May 2021
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
19 April 2021
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
22 March 2021
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
17 March 2021
New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs
01 March 2021
REPROCELL launches PCR Testing Service for COVID-19
01 March 2021
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
16 February 2021
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
10 December 2020
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
15 July 2020
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
28 February 2020
Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
13 February 2020
Early understanding of pharmacology and genomics can improve precision medicine strategies
23 December 2019
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
13 November 2019
Appointment of New Distributor in Thailand
04 November 2019
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
25 October 2019
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
25 September 2019
UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
14 March 2019
REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
12 March 2019
REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
28 February 2019
Appointment of New Distributor in China
01 February 2019
The importance of internships for life science students
19 October 2018
ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production
10 October 2018
REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER
09 October 2018
How paid internships can benefit life science students
13 September 2018
Acquisition of BioServe Biotechnologies India Pvt. Ltd.
26 April 2018
REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon
18 April 2018
Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
24 January 2018
REPROCELL Launches New Global Website
15 January 2018
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
08 November 2017
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
27 September 2017
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
10 August 2017
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
10 August 2017
REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India
24 May 2017
REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
13 April 2017
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
03 March 2017
Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)
13 January 2017
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
22 November 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
16 November 2016
REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex
16 September 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
13 May 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
21 April 2016
Alvetex in Space
14 January 2016
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
Biopta co-authors research in the European Respiratory Journal
18 November 2015
Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters
18 November 2015
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
04 November 2015
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
14 August 2015
Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
30 June 2015
Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).
20 April 2015
RSC book publication: Human-based systems for translational research
02 February 2015
REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)
09 September 2014
Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA)
05 August 2014
Scottish company creates first searchable database of human pharmacological responses in functional intact tissues
25 February 2014
Launch of Reinnervate Perfusion System for 3D cell culture
05 February 2014
Reinnervate Ltd partners with Oncotest and SBH Sciences on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture
04 November 2013
Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies
19 September 2013
Prof. Stefan Przyborski to participate at the XCellR8 Human Primary Cell Culture course, 7 November 2013
22 August 2013
3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement
07 January 2013
3D cell culture firm Reinnervate announces the release of Alvetex®Scaffold 96 well plates for high throughput 3D cell-based assays
14 December 2012
Medicyte GmbH and Reinnervate Ltd to collaborate on development of next generation predictive 3D cell toxicity assays
09 July 2012
Reinnervate and Tecan to develop automated 3D cell culture solutions for improved cellular assays
17 June 2012
Reinnervate Ltd announce Kirkstall Ltd collaboration
30 March 2012
Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®
16 November 2011
Alvetex® voted one of most technologically significant new research products by R&D magazine
27 June 2011
Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine
06 December 2010
Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture
22 November 2010
Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells
28 September 2010
Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells
28 September 2010